Minicircle
Developer of a plasmid-based, non-viral gene therapy platform for temporary systemic protein expression delivered via single subcutaneous injections. Conducts preclinical studies and IRB-governed human research, coordinates clinic-based administration through international clinical partners, and provides patient-facing digital follow-up, intake and outcome-tracking tools, including published patient testimonials and web-based contact forms.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Follistatin gene therapy (plasmid-based)
A non-viral plasmid therapy encoding follistatin intended to transiently increase circulating follistatin protein to modulate myostatin/activin pathways and potentially support increased lean mass and reduced fat.
Klotho gene therapy (plasmid-based, in development)
An investigational plasmid therapy encoding the Klotho protein, developed to target cognitive function, cellular stress response, and longevity-associated pathways; proof-of-concept trial activity reported with anticipated broader availability in 2026.
Follistatin gene therapy (plasmid-based)
A non-viral plasmid therapy encoding follistatin intended to transiently increase circulating follistatin protein to modulate myostatin/activin pathways and potentially support increased lean mass and reduced fat.
Klotho gene therapy (plasmid-based, in development)
An investigational plasmid therapy encoding the Klotho protein, developed to target cognitive function, cellular stress response, and longevity-associated pathways; proof-of-concept trial activity reported with anticipated broader availability in 2026.
Services
Coordination and delivery of single-dose, subcutaneous plasmid therapies administered on-site by licensed clinicians at partner clinics, including pre-treatment testing and short post-injection monitoring.
Design and conduct of proof-of-concept and clinical studies under IRB oversight, with multi-modal outcome data collection for safety and efficacy evaluation and preparation for publication.
Onboarding and operational support for licensed clinics to offer investigational plasmid therapies, including clinical protocols, supply logistics, and informed-consent workflows.
Coordination and delivery of single-dose, subcutaneous plasmid therapies administered on-site by licensed clinicians at partner clinics, including pre-treatment testing and short post-injection monitoring.
Design and conduct of proof-of-concept and clinical studies under IRB oversight, with multi-modal outcome data collection for safety and efficacy evaluation and preparation for publication.
Onboarding and operational support for licensed clinics to offer investigational plasmid therapies, including clinical protocols, supply logistics, and informed-consent workflows.
Expertise Areas
- Plasmid-based non-viral gene therapy development
- Subcutaneous delivery and clinic-based administration
- Translational preclinical studies in rodents and nonhuman primates
- Clinical trial design and IRB-regulated study execution
Key Technologies
- Episomal plasmid constructs
- Non-viral plasmid delivery
- DNA transformation reagent-mediated complexation
- Subcutaneous injection delivery
News & Updates
Company and its therapies are referenced in documentary and multiple press and podcast appearances listed on the press page.
Selected as a finalist and awarded milestone funding to support development of healthy-aging therapeutics.
Reported clinical access to Follistatin therapy for approximately 500 individuals; demographic note: approximately two-thirds of treated participants were male.
Company and its therapies are referenced in documentary and multiple press and podcast appearances listed on the press page.
Selected as a finalist and awarded milestone funding to support development of healthy-aging therapeutics.
Reported clinical access to Follistatin therapy for approximately 500 individuals; demographic note: approximately two-thirds of treated participants were male.